The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
The Therapeutic Potential of Psilocybin
Open accessAbstract
The psychedelic effects of some plants and fungi have been known and deliberately exploited by humans for thousands of years. Fungi, particularly mushrooms, are the principal source of naturally occurring psychedelics. The mushroom extract, psilocybin has historically been used as a psychedelic agent for religious and spiritual ceremonies, as well as a therapeutic option for neuropsychiatric conditions. Psychedelic use was largely associated with the “hippie” counterculture movement, which, in turn, resulted in a growing, and still lingering, negative stigmatization for psychedelics. As a result, in 1970, the U.S. government rescheduled psychedelics as Schedule 1 drugs, ultimately ending scientific research on psychedelics. This prohibition on psychedelic drug research significantly delayed advances in medical knowledge on the therapeutic uses of agents such as psilocybin. A 2004 pilot study from the University of California, Los Angeles, exploring the potential of psilocybin treatment in patients with advanced-stage cancer managed to reignite interest and significantly renewed efforts in psilocybin research, heralding a new age in exploration for psychedelic therapy. Since then, significant advances have been made in characterizing the chemical properties of psilocybin as well as its therapeutic uses. This review will explore the potential of psilocybin in the treatment of neuropsychiatry-related conditions, examining recent advances as well as current research. This is not a systematic review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 3×
“The Registry of Toxic Effects of Chemical Substances (RTECS) has assigned psilocybin a therapeutic index of 641, associated with a relatively better safety profile in comparison to nicotine and aspirin, with values of 21 and 199, respectively [102].”
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 2×
“Subjective effects may last between 3 and 6 h [5], after which effects subside to negligible levels [41].”
BackgroundGlobal Burden of Disease and the Impact of Mental and Addictive Disorders
Rehm, J., & Shield, K. D. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-0997-0 · Cited by 1,388
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 2×
“Pilot Study of Psilocybin Treatment for Anxiety in Patients with Advanced-Stage Cancer [33] 3.”
MethodHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Research works printed but not linked: 152
- Dyck, 2005, Flashback: Psychiatric Experimentation with LSD in Historical Perspective, Can. J. Psychiatry, 50, 381, 10.1177/070674370505000703 · DOI
- Johnson, 2017, Potential Therapeutic Effects of Psilocybin, Neurotherapeutics, 14, 734, 10.1007/s13311-017-0542-y · DOI · Paper page
- Schindler, 2015, Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey, J. Psychoact. Drugs, 47, 372, 10.1080/02791072.2015.1107664 · DOI
- Halberstadt, 2011, Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens, Neuropharmacology, 61, 364, 10.1016/j.neuropharm.2011.01.017 · DOI · Paper page
- Canal, C.E. (2018). Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action, New Psychoactive Substances; Springer Science and Business Media LLC. · DOI
- Hoyer, 1994, International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin), Pharmacol. Rev., 46, 157
- Frazer, 1999, Serotonin, Basic Neurochem., 6, 335
- Hendricks, 2015, Psilocybin, psychological distress, and suicidality, J. Psychopharmacol., 29, 1041, 10.1177/0269881115598338 · DOI
- Elflein, J. (2021, March 23). Psychedelic therapy—Statistics & Facts. Available online: https://www.statista.com/topics/4277/psychedelic-therapy/. · DOI
- Zamaria, J.A. (2016). A Phenomenological Examination of Psilocybin and its Positive and Persisting Aftereffects. NeuroQuantology, 14. · DOI
- Morgan, 2017, Tripping up addiction: The use of psychedelic drugs in the treatment of problematic drug and alcohol use, Curr. Opin. Behav. Sci., 13, 71, 10.1016/j.cobeha.2016.10.009 · DOI
- Griffiths, 2014, Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction, Curr. Drug Abuse Rev., 7, 157
- Daniel, 2017, Clinical potential of psilocybin as a treatment for mental health conditions, Ment. Health Clin., 7, 24, 10.9740/mhc.2017.01.024 · DOI
- Kim, 2014, Drugs currently in Phase II clinical trials for cocaine addiction, Expert Opin. Investig. Drugs, 23, 1105, 10.1517/13543784.2014.915312 · DOI
- Johnson, 2017, An online survey of tobacco smoking cessation associated with naturalistic psychedelic use, J. Psychopharmacol., 31, 841, 10.1177/0269881116684335 · DOI
- Wilcox, 2014, Psilocybin and Obsessive Compulsive Disorder, J. Psychoact. Drugs, 46, 393, 10.1080/02791072.2014.963754 · DOI
- Spiegel, 2016, Psilocybin-assisted psychotherapy for dying cancer patients—aiding the final trip, J. Psychopharmacol., 30, 1215, 10.1177/0269881116675783 · DOI
- Shelton, 2016, Psilocybin and palliative end-of-life care, J. Psychopharmacol., 30, 1207, 10.1177/0269881116675764 · DOI
- Lyons, 2018, Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression, J. Psychopharmacol., 32, 811, 10.1177/0269881117748902 · DOI · Paper page
- Beck, S. (2020). Psilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms. Physician Assist. Stud. Stud. Artic., 7. · DOI
- Reynolds, C.F. (2020). Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression—Quo Vadis?. JAMA Psychiatry. · DOI
- Roseman, L., Nutt, D.J., and Carhart-Harris, R.L. (2018). Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Front. Pharmacol., 8. · DOI · Paper page
- Sewell, 2006, Response of cluster headache to psilocybin and LSD, Neurology, 66, 1920, 10.1212/01.wnl.0000219761.05466.43 · DOI · Paper page
- Whelan, 2018, Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: A potential role?, Pain Manag., 8, 217, 10.2217/pmt-2017-0068 · DOI
- Nkadimeng, S.M., Nabatanzi, A., Steinmann, C.M.L., and Eloff, J.N. (2020). Phytochemical, Cytotoxicity, Antioxidant and Anti-Inflammatory Effects of Psilocybe Natalensis Magic Mushroom. Plants, 9. · DOI
- Castellanos, 2020, Chronic pain and psychedelics: A review and proposed mechanism of action, Reg. Anesth. Pain Med., 45, 486, 10.1136/rapm-2020-101273 · DOI
- Ramachandran, 2018, Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF), Neurocase, 24, 105, 10.1080/13554794.2018.1468469 · DOI
- Hendricks, P.S. (2020). Psilocybin-assisted group therapy: A new hope for demoralization. EClinicalMedicine, 27. · DOI
- Meldrum, 1971, Effects of psilocybin, dimethyltryptamine, mescaline and various lysergic acid derivatives on the EEG and on photically induced epilepsy in the baboon (Papio papio), Electroencephalogr. Clin. Neurophysiol., 31, 563, 10.1016/0013-4694(71)90072-1 · DOI
- Nichols, 2020, Psilocybin: From ancient magic to modern medicine, J. Antibiot., 73, 679, 10.1038/s41429-020-0311-8 · DOI · Paper page
- Heffter, 1898, Ueber Pellote, Arch. Exp. Pathol. Pharmakol., 40, 385, 10.1007/BF01825267 · DOI
- Schultes, 1969, Hallucinogens of Plant Origin, Science, 163, 245, 10.1126/science.163.3864.245 · DOI · Paper page
- Mithoefer, 2016, Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA, Lancet Psychiatry, 3, 481, 10.1016/S2215-0366(15)00576-3 · DOI · Paper page
- Brenan, 1980, Plants of the Gods: Origins of Hallucinogenic Use, Kew Bull., 35, 708, 10.2307/4110029 · DOI
- 2015, Hallucinogenic drugs in pre-Columbian Mesoamerican cultures, Neurologia (Barcelona, Spain), 30, 42
- Davies, 1964, Lysergic acid (LSD 25) and ritalin in the treatment of neurosis, J. Psychosom. Res., 8, 164, 10.1016/0022-3999(64)90081-9 · doi:10.1016/0022-3999(64)90081-9
- Johnson, 1969, LSD in the Treatment of Alcoholism, Am. J. Psychiatry, 126, 481, 10.1176/ajp.126.4.481 · DOI
- Ludwig, 1969, A Clinical Study of LSD Treatment in Alcoholism, Am. J. Psychiatry, 126, 59, 10.1176/ajp.126.1.59 · DOI
- Smart, 1964, The efficacy of LSD in the treatment of alcoholism, Q. J. Stud. Alcohol, 25, 333, 10.15288/qjsa.1964.25.333 · DOI
- Visotsky, 1971, LSD and alcoholism: A clinical study of treatment efficacy, J. Chronic Dis., 24, 597, 10.1016/0021-9681(71)90050-6 · DOI
- Jordy, 1971, Book Reviews—LSD and alcoholism; a clinical study of treatment efficacy, Q. J. Stud. Alcohol, 32, 589, 10.15288/qjsa.1971.32.589 · doi:10.15288/qjsa.1971.32.589
- Dahlberg, 1968, Lysergic Acid Diethylamide (LSD) in the Treatment of Alcoholism, Arch. Gen. Psychiatry, 19, 508, 10.1001/archpsyc.1968.01740100124021 · DOI
- Abuzzahab, 1971, A review of LSD treatment in alcoholism, Int. Pharm., 6, 223
- Dyck, 2015, LSD: A new treatment emerging from the past, CMAJ Can. Med Assoc. J. J. l’Association Med Can., 187, 1079, 10.1503/cmaj.141358 · DOI
- Rice, 1992, An evaluation of a maximum security therapeutic community for psychopaths and other mentally disordered offenders, Law Hum. Behav., 16, 399, 10.1007/BF02352266 · DOI · Paper page
- Harris, 1994, Psychopaths: Is a therapeutic community therapeutic?, Int. J. Ther. Supportive Organ., 15, 283
- Reidy, 2013, Reducing psychopathic violence: A review of the treatment literature, Aggress. Violent Behav., 18, 527, 10.1016/j.avb.2013.07.008 · DOI
- Bender, 1961, Treatment of autistic schizophrenic children with LSD-25 and UML-491, Recent Adv. Biol. Psychiatry, 4, 170
- Bender, 1966, D-lysergic acid in the treatment of the biological features of childhood schizophrenia, Dis. Nerv. Syst., 7, 43
- Freedman, 1962, Autistic schizophrenic children. An experiment in the use of d-lysergic acid diethylamide (LSD-25), Arch. Gen. Psychiatry, 6, 203, 10.1001/archpsyc.1962.01710210019003 · DOI
- Simmons, 1972, The variable effects of LSD-25 on the behavior of a heterogeneous group of childhood schizophrenics, Behav. Neuropsychiatry, 4, 10
- Moller, 1964, The treatment of childhood schizophrenia in a public school system, Psychol. Sch., 1, 297, 10.1002/1520-6807(196407)1:3<297::AID-PITS2310010316>3.0.CO;2-T · doi:10.1002/1520-6807(196407)1:3<297::aid-pits2310010316>3.0.co;2-t
- Ball, 1961, The Use of L.S.D. 25 (D-Lysergic Acid Diethylamide) in the Treatment of the Sexual Perversions, Can. Psychiatr. Assoc. J., 6, 231, 10.1177/070674376100600407 · DOI
- Simmons, 1966, Modification of autistic behavior with LSD-25, Am. J. Psychiatry, 122, 1201, 10.1176/ajp.122.11.1201 · DOI
- Sigafoos, 2007, Flashback to the 1960s: LSD in the treatment of autism, Dev. Neurorehabilit., 10, 75, 10.1080/13638490601106277 · DOI
- Honigfeld, 1964, Temporal effects of LSD-25 and epinephrine on verbal behavior, PsycEXTRA Dataset, 70, 303
- Timothy, 1965, A new behavior change program using psilocybin, Psychotherapy, 2, 61, 10.1037/h0088612 · DOI
- Keusch, 2017, Rehabilitation in patients with pulmonary arterial hypertension, Swiss Med. Week., 147, w14462
- Leary, 1969, The effects of consciousness-expanding drugs on prisoner rehabilitation, Psychedelic Rev., 10, 29
- Doblin, 1991, Pahnke’s "Good Friday experiment": A long-term follow-up and methodological critique, J. Transpers. Psychol., 23, 1
- Kargbo, 2020, Psilocybin Therapeutic Research: The Present and Future Paradigm, ACS Med. Chem. Lett., 11, 399, 10.1021/acsmedchemlett.0c00048 · DOI
- Hoch, 1952, Effects of mescaline and lysergic acid (d-LSD-25), Am. J. Psychiatry, 108, 579, 10.1176/ajp.108.8.579 · DOI
- Bahr, 2019, Intranasal Esketamine (SpravatoTM) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant, P T Peer-Rev. J. Formul. Manag., 44, 340
- Stamets, P., and Weil, A. (1996). Psilocybin Mushrooms of the World: An Identification Guide, Ten Speed Press. [1st ed.].
- Griffiths, R.R., Hurwitz, E.S., Davis, A.K., Johnson, M.W., and Jesse, R. (2019). Survey of subjective “God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS ONE, 14. · DOI · Paper page
- Barrett, F.S., Krimmel, S.R., Griffiths, R.R., Seminowicz, D.A., and Mathur, B.N. (2020). Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. NeuroImage, 218. · DOI · Paper page
- Carbonaro, 2020, Subjective features of the psilocybin experience that may account for its self-administration by humans: A double-blind comparison of psilocybin and dextromethorphan, Psychopharmacology, 237, 2293, 10.1007/s00213-020-05533-9 · DOI
- Griffiths, 2008, Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later, J. Psychopharmacol., 22, 621, 10.1177/0269881108094300 · DOI · Paper page
- Doblin, 1998, Dr. Leary’s Concord Prison Experiment: A 34-Year Follow-up Study, J. Psychoact. Drugs, 30, 419, 10.1080/02791072.1998.10399715 · DOI
- Leary, 1963, Reactions to psilocybjn administered in a supportive environment, J. Nerv. Ment. Dis., 137, 561, 10.1097/00005053-196312000-00007 · DOI · Paper page
- Kelmendi, 2016, The role of psychedelics in palliative care reconsidered: A case for psilocybin, J. Psychopharmacol., 30, 1212, 10.1177/0269881116675781 · DOI
- Guss, J., Krause, R., and Sloshower, J. (2020). The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame). PsyArXiv. · DOI
- Yale University (2021, March 25). Psilocybin for the Treatment of Cluster Headache, Available online: https://clinicaltrials.gov/ct2/show/NCT02981173. · DOI
- Petranker, R., Kim, J., and Anderson, T. (2020). Microdosing as a response to the meaning crisis. PsyArXiv. · DOI
- Petranker, R., Anderson, T., Maier, L.J., Barratt, M.J., A Ferris, J., and Winstock, A.R. (2020). Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. J. Psychopharmacol. · DOI
- Hasler, 1997, Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man, Pharm. Acta Helv., 72, 175, 10.1016/S0031-6865(97)00014-9 · DOI · Paper page
- 2014, Psilocybin Summary of knowledge and new perspectives, Eur. Neuropsychopharmacol., 24, 342, 10.1016/j.euroneuro.2013.12.006 · DOI · Paper page
- Horita, 1963, Some biochemical studies on psilocybin and psilogin, J. Neuropsychiatr., 4, 270
- Fricke, 2020, Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin, Chem. A Eur. J., 26, 8281, 10.1002/chem.202000134 · DOI
- Nichols, 1999, Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin, Synthesis, 1999, 935, 10.1055/s-1999-3490 · DOI
- Ullrich, 2007, Enzymatic hydroxylation of aromatic compounds, Cell. Mol. Life Sci., 64, 271, 10.1007/s00018-007-6362-1 · DOI · Paper page
- Fricke, 2017, Enzymatic Synthesis of Psilocybin, Angew. Chem. Int. Ed., 56, 12352, 10.1002/anie.201705489 · DOI · Paper page
- Hoefgen, 2018, Facile assembly and fluorescence-based screening method for heterologous expression of biosynthetic pathways in fungi, Metab. Eng., 48, 44, 10.1016/j.ymben.2018.05.014 · DOI
- Adams, 2019, In vivo production of psilocybin in E. coli, Metab. Eng., 56, 111, 10.1016/j.ymben.2019.09.009 · DOI
- Milne, 2020, Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives, Metab. Eng., 60, 25, 10.1016/j.ymben.2019.12.007 · DOI
- Borodina, 2014, Advances in metabolic engineering of yeast Saccharomyces cerevisiae for production of chemicals, Biotechnol. J., 9, 609, 10.1002/biot.201300445 · DOI · Paper page
- Hassan, Z., Bosch, O.G., Singh, D., Narayanan, S., Kasinather, B.V., Seifritz, E., Kornhuber, J., Quednow, B.B., and Müller, C.P. (2017). Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs. Front. Psychiatry, 8. · DOI
- Nava, 2019, Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines, Adv. Pharmacol. Sci., 2019, 1
- Mahapatra, 2017, Role of psilocybin in the treatment of depression, Ther. Adv. Psychopharmacol., 7, 54, 10.1177/2045125316676092 · DOI
- Holtzheimer, 2011, Stuck in a rut: Rethinking depression and its treatment, Trends Neurosci., 34, 1, 10.1016/j.tins.2010.10.004 · DOI · Paper page
- Grimm, 2018, Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination, Eur. Neuropsychopharmacol., 28, 691, 10.1016/j.euroneuro.2018.03.016 · DOI
- Tagliazucchi, 2014, Enhanced repertoire of brain dynamical states during the psychedelic experience, Hum. Brain Mapp., 35, 5442, 10.1002/hbm.22562 · DOI · Paper page
- Lord, 2019, Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin, NeuroImage, 199, 127, 10.1016/j.neuroimage.2019.05.060 · DOI · Paper page
- Bortolozzi, 2010, Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors, Int. J. Neuropsychopharmacol., 13, 1299, 10.1017/S146114571000009X · DOI
- Schellekens, 2016, Psilocybin for treating substance use disorders?, Expert Rev. Neurother., 17, 203
- Nagaeva, E., Zubarev, I., Gonzales, C.B., Forss, M., Nikouei, K., De Miguel, E., Elsilä, L., Linden, A.-M., Hjerling-Leffler, J., and Augustine, G.J. (2020). Heterogeneous somatostatin-expressing neuron population in mouse ventral tegmental area. eLife, 9. · DOI
- Dailly, 2004, Dopamine, depression and antidepressants, Fundam. Clin. Pharmacol., 18, 601, 10.1111/j.1472-8206.2004.00287.x · DOI · Paper page
- Maust, 2016, Agitation in Alzheimer Disease as a Qualifying Condition for Medical Marijuana in the United States, Am. J. Geriatr. Psychiatry, 24, 1000, 10.1016/j.jagp.2016.03.006 · DOI
- Grandjean, J., Buehlmann, D., Buerge, M., Sigrist, H., Seifritz, E., Vollenweider, F.X., Pryce, C.R., and Rudin, M. (2021). Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. NeuroImage, 225. · DOI
- Coull, 2010, Neuroanatomical and Neurochemical Substrates of Timing, Neuropsychopharmacology, 36, 3, 10.1038/npp.2010.113 · DOI · Paper page
- Hindley, 2020, Psychiatric symptoms abused by cannabis constituents: A systematic review and meta-analysis, Lancet Psychiatry, 7, 344, 10.1016/S2215-0366(20)30074-2 · DOI · Paper page
- Geyer, 2015, Lysergic Acid Diethylamide and Psilocybin Revisited, Biol. Psychiatry, 78, 516, 10.1016/j.biopsych.2015.08.003 · DOI
- Mertens, 2020, Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression, J. Psychopharmacol., 34, 167, 10.1177/0269881119895520 · DOI · Paper page
- Stroud, 2018, Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression, Psychopharmacol., 235, 459, 10.1007/s00213-017-4754-y · DOI
- Creese, 1975, The dopamine receptor: Differential binding of d-LSD and related agents to agonist and antagonist states, Life Sci., 17, 1715, 10.1016/0024-3205(75)90118-6 · DOI · Paper page
- Roseman, L., Leech, R., Feilding, A., Nutt, D.J., and Carhart-Harris, R.L. (2014). The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Front. Hum. Neurosci., 8. · DOI · Paper page
- Kong, 2013, Functional connectivity between the amygdala and prefrontal cortex in medication-naive individuals with major depressive disorder, J. Psychiatry Neurosci., 38, 417, 10.1503/jpn.120117 · DOI · Paper page
- IIsbell, 1959, Comparison of the reactions induced by psilocybin and LSD-25 in man, Psychopharmacol., 1, 29, 10.1007/BF00408109 · DOI
- Hollister, 1961, Clinical, biochemical and psychologic effects of psilocybin, Arch. Int. Pharmacodyn. Ther., 130, 42
- James, E., Robertshaw, T.L., Hoskins, M., and Sessa, B. (2020). Psilocybin occasioned mystical-type experiences. Hum. Psychopharmacol. Clin. Exp., 35. · DOI
- Erritzoe, 2018, Effects of psilocybin therapy on personality structure, Acta Psychiatr. Scand., 138, 368, 10.1111/acps.12904 · DOI · Paper page
- Forstmann, 2017, Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness, J. Psychopharmacol., 31, 975, 10.1177/0269881117714049 · DOI
- Hendricks, 2018, The relationships of classic psychedelic use with criminal behavior in the United States adult population, J. Psychopharmacol., 32, 37, 10.1177/0269881117735685 · DOI
- Walsh, 2016, Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use, J. Psychopharmacol., 30, 601, 10.1177/0269881116642538 · DOI
- Hendricks, 2015, Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population, J. Psychopharmacol., 29, 280, 10.1177/0269881114565653 · DOI · Paper page
- MacLean, 2011, Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness, J. Psychopharmacol., 25, 1453, 10.1177/0269881111420188 · DOI · Paper page
- Nour, 2017, Psychedelics, Personality and Political Perspectives, J. Psychoact. Drugs, 49, 182, 10.1080/02791072.2017.1312643 · DOI · Paper page
- Miller, 2004, The phenomenon of quantum change, J. Clin. Psychol., 60, 453, 10.1002/jclp.20000 · DOI · Paper page
- Sherwood, 2020, Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin, J. Nat. Prod., 83, 461, 10.1021/acs.jnatprod.9b01061 · DOI
- Blei, 2020, Simultaneous Production of Psilocybin and a Cocktail of β-Carboline Monoamine Oxidase Inhibitors in “Magic” Mushrooms, Chemistry, 26, 729, 10.1002/chem.201904363 · DOI
- Gartz, 1989, Biotransformation of tryptamine derivatives in mycelial cultures ofPsilocybe, J. Basic Microbiol., 29, 347, 10.1002/jobm.3620290608 · DOI
- Matsushima, 2009, Effects of Psilocybe argentipes on marble-burying behavior in mice, Biosci. Biotechnol. Biochem., 73, 1866, 10.1271/bbb.90095 · DOI
- Gartz, 1987, Variation of the amount of Alkaloids in Fruit Bodies of Inocybe aeruginascens, Planta Med., 53, 539, 10.1055/s-2006-962805 · doi:10.1055/s-2006-962805
- Jensen, 2006, Aeruginascin, a Trimethylammonium Analogue of Psilocybin from the Hallucinogenic Mushroom Inocybe aeruginascens, Planta Med., 72, 665, 10.1055/s-2006-931576 · DOI
- Chadeayne, 2020, Active Metabolite of Aeruginascin (4-Hydroxy-N,N,N-trimethyltryptamine): Synthesis, Structure, and Serotonergic Binding Affinity, ACS Omega, 5, 16940, 10.1021/acsomega.0c02208 · DOI
- Gartz, 1989, Analysis of Aeruginascin in Fruit Bodies of the Mushroom Inocybe aeruginascens, Int. J. Crude Drug Res., 27, 141, 10.3109/13880208909053954 · DOI
- Fricke, 2019, Production Options for Psilocybin: Making of the Magic, Chem. A Eur. J., 25, 897, 10.1002/chem.201802758 · DOI
- 1975, Factors affecting drug action, Aust. Nurses J., 4, 21
- Ona, 2018, Inside bad trips: Exploring extra-pharmacological factors, J. Psychedelic Stud., 2, 53, 10.1556/2054.2018.001 · DOI
- Subra, 2009, A message in a bottle: Extrapharmacological effects of alcohol on aggression, J. Exp. Soc. Psychol., 45, 137, 10.1016/j.jesp.2008.07.018 · DOI
- Ahmed, 2020, Non-pharmacological factors that determine drug use and addiction, Neurosci. Biobehav. Rev., 110, 3, 10.1016/j.neubiorev.2018.08.015 · DOI
- Olson, 2020, Tripping on nothing: Placebo psychedelics and contextual factors, Psychopharmacology, 237, 1371, 10.1007/s00213-020-05464-5 · DOI
- Peden, 1982, The Problem of Psilocybin Mushroom Abuse, Hum. Toxicol., 1, 417, 10.1177/096032718200100408 · DOI
- Hyde, 1978, Abuse of Indigenous Psilocybin Mushrooms: A New Fashion and Some Psychiatric Complications, Br. J. Psychiatry, 132, 602, 10.1192/bjp.132.6.602 · DOI
- Vollenweider, 1998, Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action, NeuroReport, 9, 3897, 10.1097/00001756-199812010-00024 · DOI · Paper page
- Opperhuizen, 2011, Harm potential of magic mushroom use: A review, Regul. Toxicol. Pharmacol., 59, 423, 10.1016/j.yrtph.2011.01.006 · DOI · Paper page
- Jo, 2014, Toxicological Profiles of Poisonous, Edible, and Medicinal Mushrooms, Mycobiology, 42, 215, 10.5941/MYCO.2014.42.3.215 · doi:10.5941/myco.2014.42.3.215
- Bouso, 2018, Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews, Expert Rev. Clin. Pharmacol., 11, 889, 10.1080/17512433.2018.1511424 · DOI · Paper page
- Gable, 1993, Toward a Comparative Overview of Dependence Potential and Acute Toxicity of Psychoactive Substances Used Nonmedically, Am. J. Drug Alcohol Abus., 19, 263, 10.3109/00952999309001618 · DOI
- Gable, 2004, Comparison of acute lethal toxicity of commonly abused psychoactive substances, Addiction, 99, 686, 10.1111/j.1360-0443.2004.00744.x · DOI · Paper page
- Fantegrossi, 2004, Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys, Behav. Pharmacol., 15, 149, 10.1097/00008877-200403000-00007 · DOI · Paper page
- Lim, 2012, A fatal case of ‘magic mushroom’ ingestion in a heart transplant recipient, Intern. Med. J., 42, 1268, 10.1111/j.1445-5994.2012.02955.x · DOI
- 2013, Suizid unter Psilocin-Einfluss [Suicide under the influence of “magic mushrooms”], Arch. Kriminol., 231, 193
- Byock, 2018, Taking Psychedelics Seriously, J. Palliat. Med., 21, 417, 10.1089/jpm.2017.0684 · DOI · Paper page
- Appel, 1968, Tolerance and cross-tolerance among psychotomimetic drugs, Psychopharmacol., 13, 267, 10.1007/BF00401404 · DOI
- Passie, 2008, The Pharmacology of Lysergic Acid Diethylamide: A Review, CNS Neurosci. Ther., 14, 295, 10.1111/j.1755-5949.2008.00059.x · DOI · Paper page
- Strassman, R. (2008). Inner Paths to Outer Space: Journeys to Alien Worlds through Psychedelics and Other Spiritual Technologies, Paperback Edition; Park Street Press.
- Freye, E. (2009). The Mushroom Psilocybin with Psychedelic Properties. Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs, Springer Science and Business Media LLC. · DOI
- Gable, 2006, The Toxicity of Recreational Drugs, Am. Sci., 94, 207, 10.1511/2006.59.206 · doi:10.1511/2006.59.206
- Hasler, 2002, Renal excretion profiles of psilocin following oral administration of psilocybin: A controlled study in man, J. Pharm. Biomed. Anal., 30, 331, 10.1016/S0731-7085(02)00278-9 · DOI
- Kamata, 2006, Direct detection of serum psilocin glucuronide by LC/MS and LC/MS/MS: Time-courses of total and free (unconjugated) psilocin concentrations in serum specimens of a “magic mushroom” user, Forensic Toxicol., 24, 36, 10.1007/s11419-006-0006-2 · DOI
- Shoda, 2011, Enzyme-assisted synthesis of the glucuronide conjugate of psilocin, an hallucinogenic component of magic mushrooms, Drug Test. Anal., 3, 594, 10.1002/dta.244 · DOI
Cited by
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
Haikazian, S., Chen-Li, D. C. J., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115531 · Cited by 134
Van Court, R. C., Wiseman, M. S., Meyer, K. W., Ballhorn, D. J., Amses, K. R., Slot, J. C., Dentinger, B. T. M., Garibay-Orijel, R., & Uehling, J. K. (2022) · Fungal Biology · doi:10.1016/j.funbio.2022.01.003 · Cited by 94
Update on treatments for anxiety-related disorders
Lee, H. J., & Stein, M. B. (2023) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000841 · Cited by 43
Pepe, M., Hesami, M., de la Cerda, K. A., Perreault, M. L., Hsiang, T., & Jones, A. M. P. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108247 · Cited by 36
Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome
Buzzelli, V., Carbone, E., Manduca, A., Schiavi, S., Feo, A., Perederiy, J. V., Ambert, K. H., Hausman, M., & Trezza, V. (2023) · Psychopharmacology · doi:10.1007/s00213-022-06286-3 · Cited by 22
Metadata
- Authors
- Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-05-15
- Volume
- 26
- Issue
- 10
- Pages
- 2948
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3161556967
- Cited by
- 242
- References
- 57
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Therapeutic Potential of Psilocybin. https://app.cochat.ai/papers/10.3390/molecules26102948
- The paper
- Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021). The Therapeutic Potential of Psilocybin. Molecules. https://doi.org/10.3390/molecules26102948
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.